The Clinical and Financial Implications of Immediate or Deferred Treatment in Patients with Advanced Prostatic Cancer
Cancer of the prostate may be diagnosed because of symptoms of outflow obstruction, the effect of the local tumour on surrounding organs including the bladder (haematuria) and rectum (constipation or a feeling of fullness), by extension to the peritoneum producing discomfort, or by symptoms from metastases (occult cancer). It may come to light coincidentally following a prostatectomy for what was thought to have been benign disease (latent cancer) and is increasingly being diagnosed in Western Europe and the United States following routine health screening. Once diagnosed, the management will be determined by the stage of the disease and the therapeutic inclination of the surgeon.
KeywordsProstatic Cancer Medroxyprogesterone Acetate Cyproterone Acetate Estramustine Phosphate Prostatic Capsule
Unable to display preview. Download preview PDF.
- 1.Pavone-Macaluso M et al: Comparison of diethylstilbestrol cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomised Phase ill trial of the European Organisation for Research and Treatment of Cancer Urological Group. J Urol 1986 (136):624–631PubMedGoogle Scholar
- 3.Veterans Administration Co-operative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967 (124):1011–1017Google Scholar
- 4.Andersson L et al: Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma: a randomised study. Scand J Urol Nephrol 1980 (55, Suppl):143–145Google Scholar
- 6.De Voogt et al: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organisation for Research and Treatment of Cancer trials 30761 and 30762. J Urol 1986 (135/2):303–307PubMedGoogle Scholar
- 9.Scott WW: Panel discussion on some aspects of urological endocrinology. In: North Central Section of the American Urological Association Postgraduate Seminar. Burger, Minneapolis, p 211. Cited by Thompson GJ: Long term control of prostatic cancer. Surg Clin North Am 1958 (39):963–971Google Scholar
- 12.Paulson DF: Multi modal therapy of prostatic cancer. J Urol 1981 (17):53Google Scholar
- 13.Newling DWW et al: The natural history of prostatic cancer - the argument for a no treatment policy. In: Pavone- Macaluso M, Smith PH and Bagshaw MA (eds) Testicular Cancer and other tumors of the Genito-Urinary Tract. Alan R Liss, New York 1985 pp 443–448Google Scholar
- 15.Handley RC et al: Deferred treatment for prostatic cancer. Br J Urol 1987 (in press)Google Scholar
- 17.Byar DP: VACURG studies of post-prostatectomy survival. Scand J Urol Nephrol 1980 (55, Suppl):113–116Google Scholar
- 18.Byar DP: Review of the Veterans Administration Studies of cancer of the prostate and new results concerning treatment of stage I and II tumours. In: Pavone-Macaluso M, Smith PH and Edsmyr F (eds) Bladder Tumors and other Topics in Urological Oncology. Plenum, New York 1979 pp 471–492Google Scholar
- 19.Paulson DF: Treatment of locally confined prostatic cancer: radiotherapy versus surgery; limits of curability. In: Kurth KH, Debruyne FMJ, Schröder FJ, Splinter TAW and Wagener TDJ (eds) Progress and Controversies in Oncological Urology. Alan R Liss, New York 1984 pp 483–492Google Scholar
- 20.Stamey TA: Monographs in Urology 1985 (6):105Google Scholar